^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-12 modulator

    Related drugs:
    2d
    A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients (clinicaltrials.gov)
    P1, N=57, Recruiting, Kangabio AUSTRALIA LTD PTY
    New P1 trial
    |
    Enweida (envafolimab)
    10ms
    This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Kangabio AUSTRALIA LTD PTY | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Enweida (envafolimab)
    1year
    A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer (clinicaltrials.gov)
    P1, N=190, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    sasanlimab (PF-06801591)
    over1year
    This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=54, Recruiting, Kangabio AUSTRALIA LTD PTY | Not yet recruiting --> Recruiting | N=27 --> 54 | Trial completion date: Sep 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Enweida (envafolimab)
    over1year
    Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=218, Recruiting, Suzhou Abogen Biosciences Co., Ltd. | N=160 --> 218 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • ABO2011
    over1year
    Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Suzhou Abogen Biosciences Co., Ltd. | Enrolling by invitation --> Recruiting | Phase classification: P1 --> P1/2 | N=40 --> 160 | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2025
    Enrollment status • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    ABO2011
    almost2years
    Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence. (PubMed, Acta Pharm Sin B)
    Mechanistically, CARG-2020 potently activates Th1 immune mechanisms and inhibits expression of genes related to T cell exhaustion and cancer-promoting inflammation. The ability of CARG-2020 to prevent tumor recurrence and to provide survival benefit makes it a promising candidate for its development for human cancer immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A)
    |
    CARG-2020
    2years
    A Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=40, Enrolling by invitation, Suzhou Abogen Biosciences Co., Ltd. | Recruiting --> Enrolling by invitation
    Enrollment status • Metastases
    |
    ABO2011
    almost3years
    RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma (clinicaltrials.gov)
    P1/2, N=7, Terminated, Repertoire Immune Medicines | Trial completion date: May 2024 --> Oct 2022 | Active, not recruiting --> Terminated | Trial primary completion date: May 2024 --> Sep 2022; Development program terminated
    Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    PD-1 expression
    |
    RPTR-168
    3years
    Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy. (PubMed, Front Oncol)
    Efficacy studies demonstrated that combination with T7011 and CAR-T or CAR-T cells showed significant synergistic anti-tumor responses in several solid tumor models. These studies indicated that the new generation of oHSV T7011 can be a promising combinational therapy with CD19 or BCMA-specific CAR T cells for the treatment of a broad range of solid tumors.
    Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    MVR-C5252
    3years
    A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity (SITC 2022)
    Conclusions BCA356 specifically targets CAIX-expressing tumour cells and similar to wild type IL-12 cytokine, has the potential to reduce tumour proliferation with optimal activation of pro-inflammatory cytokines. Through these in vitro and in vivo studies, we demonstrate that BCA356 by its CAIX-targeted IL-12v delivery approach is both efficacious and safe.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • CA9 (Carbonic anhydrase 9) • STAT4 (Signal Transducer And Activator Of Transcription 4)
    |
    CD8 expression • CA9 overexpression • CA9 expression
    |
    BCA356
    3years
    Pharmacologically-controlled expression of membrane-bound IL-12 results in T-cell therapy with enhanced potency in preclinical solid tumor models (SITC 2022)
    Here, we use a DRD derived from carbonic anhydrase 2 and the FDA-approved inhibitor acetazolamide (ACZ) as a stabilizing ligand...Conclusions The cytoDRiVE® platform enables enhanced regulation of IL-12 armored T-cells in multiple preclinical solid tumor models, potentiating an improved therapeutic window for IL12 in ACT. Ethics Approval All animals studies were IACUC approved.
    Preclinical
    |
    CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    acetazolamide